| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.07. | AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical | ||
| 13.07. | Bristol Myers Squibb's New Drug Application for mezigdomide accepted by FDA | ||
| 13.07. | Exonate appoints Olav Hellebø as CEO | ||
| 10.07. | Boehringer Ingelheim's Jascayd approved by MHRA for idiopathic pulmonary fibrosis | ||
| 10.07. | Ipsen to acquire Memo Therapeutics in deal worth more than €700m | ||
| 09.07. | Medical-Commercial alignment in rare disease launches: what breaks first? | ||
| 09.07. | Teva submits FDA application for paediatric Tourette syndrome therapy | ||
| 08.07. | Vertex to acquire Crinetics in deal worth around $10.0bn | ||
| 08.07. | The UK's life sciences' crossroads: competing in a market defined by speed, scale and investment | ||
| 07.07. | Novartis to acquire Myricx Bio in deal worth $1.5bn | ||
| 07.07. | Launching into an AI-powered future: a prescription for success | ||
| 06.07. | Klick Health acquires Oxford PharmaGenesis | ||
| 06.07. | ASCO 2026: the art of translation | ||
| 03.07. | Communiqué Awards 2026: Healthcare Communiquétor Neil Flash | ||
| 03.07. | Communiqué Awards 2026: celebrating excellence in healthcare communications | ||
| 02.07. | Sanofi announces phase 3 study data for infantile-onset Pompe disease | ||
| 02.07. | The outcomes economy: where next for pharma? | ||
| 01.07. | Zymeworks to acquire Theravance Biopharma in deal worth $929m | ||
| 01.07. | Achieving launch excellence through cross-functional collaboration | ||
| 30.06. | Roche's Enspryng given FDA Priority Review as thyroid eye disease treatment | ||
| 30.06. | Steering generative AI into the pharma fast lane | ||
| 29.06. | Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim | ||
| 26.06. | Pfizer announces phase 3 results for potential non-small cell lung cancer treatment | ||
| 26.06. | MRM Health appoints Hans-Jürgen Wörle as Independent Director | ||
| 25.06. | MRM Health appoints Michel Detheux as Chairman of the Board |